1. New Zealand Stocks

  2. •

    Health technology

  3. •

    Biotechnology
BLIS Technologies Limited

BLIS Technologies Limited

NNZX:BLT
0.03
NZD
0.00
(0.00%)
0.00EPS
21.37P/E
17.91MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
0.01
0.01
- -
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.01
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
0.01
Tangible Book Value per Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
Basic Weighted Avg Shares
530
856
1,102
1,102
1,107
1,108
1,108
1,108
1,108
1,230
1,274
1,274
1,279
Sales/Revenue/Turnover
1
1
3
6
7
5
8
10
10
9
10
10
12
Operating Margin (%)
-213.2
-165.64
-80.86
-24.96
-9.84
-19.62
-5.12
6.91
-3.18
-44.97
-24.35
-12.3
-10.25
Depreciation Expense
1
- -
1
1
1
1
1
- -
- -
1
1
1
1
Net Income, GAAP
-2
-2
-1
-1
- -
-1
- -
2
1
-3
-1
1
1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.18
5.95
Profit Margin (%)
-161.46
-122.01
-54.42
-14.5
-0.37
-19.72
4.7
15.34
5.47
-30.77
-13.57
6.16
7.25
Working Capital
1
4
3
2
2
2
2
4
3
10
9
10
10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
Total Equity
3
6
5
4
4
3
3
5
6
12
11
11
12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-11
14.76
-5.57
- -
- -
-10.26
-8.99
Return on Capital (%)
- -
- -
- -
- -
- -
- -
10.68
33.36
10.02
- -
- -
5.78
6.96
Return on Common Equity (%)
- -
-31.88
-25.01
-18.57
-0.6
-29.67
11.85
37.8
10.52
-30.4
-11.75
5.79
7.04

Capital Structure

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

NZD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.92%
25.81%
7.26%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
347.49%
-162.6%
29.72%
Sales/Revenue/Turnover
21.51%
2.56%
10.27%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
10
2024
- -
- -
10
2025
- -
- -
12

Semi-annual Earnings Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Scott Johnson
Full Time Employees
32
Sector
Health technology
Industry
Biotechnology
Address
442 Moray Place Dunedin OTA New Zealand 9016
IPO Date
Jul 30, 2001
Website
blis.co.nz
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
BLIS Technologies Limited (NZX: BLT) is a biotechnology company that develops, manufactures, and commercializes advanced probiotic strains for targeted health applications, including oral, throat, dental, immune, and skin health. The company offers proprietary strains such as BLIS K12 (Streptococcus salivarius K12) for supporting ear, nose, and throat (ENT) health, immunity, and bad breath reduction; BLIS M18 (Streptococcus salivarius M18) for promoting teeth and gum health and dental hygiene; and BLIS Q24 (Micrococcus luteus Q24) for balancing the skin microbiome to enhance skin clarity and radiance; these strains are provided as ingredients for private label and customized solutions, as well as finished products including lozenges, serums, and supplements in formats such as probiotic serum, teeth and gums lozenges, fresh breath lozenges, and immune lozenges. BLIS Technologies Limited, founded in 2000 and headquartered in Dunedin, New Zealand, operates globally with key markets in North America, Asia-Pacific (including China), Europe, Middle East, Africa, and New Zealand, serving B2B partners in ingredient supply, private label manufacturing, and finished goods alongside direct-to-consumer channels via e-commerce and retail. Recent developments include a strengthened strategic alliance with Probi AB in October 2025, extending the technology license and distribution agreement to grant Probi exclusive rights for BLIS K12 and BLIS M18 strains in the USA, Canada, select EMEA markets, and newly for pet nutrition applications; a new five-year agreement with BioStix Pty Ltd (BSP) in July 2025 following settlement of a patent issue; a new distribution partnership with Wilson Consumer Products Limited for the New Zealand pharmacy channel; and robust first-half 2026 financial results announced in November 2025, featuring 28% revenue growth to $7.7 million driven by 39% B2B expansion and private-label gains in China.